Investment, partnering and strategy at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
12 organizations at TPD Summit 2026 present work in investment, partnering & strategy: 10 drug developers and 2 technology and service providers. Between them they bring 25 presentations to the program. Most represented: Nurix Therapeutics (4 on the program), Amgen (2 on the program), Arvinas (2 on the program). 8 of them have their own page in this guide. As of Oct 20, 2026.
Format
Top represented
Showing 1–12 of 12 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Nurix Therapeutics San Francisco, CA | ◇Industry Partner |
Clinical-stage biotech developing targeted protein degraders, including BTK degraders, for cancer and inflammatory diseases. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Tue Oct 27 12:30pm Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 9:00am Session Details to be Announced AI & computational design |
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company with medicines in oncology, inflammation, cardiovascular and bone disease, and induced proximity research. | Chair Wed Oct 28 8:20am Chair’s Opening Remarks Investment, partnering & strategy Talk Wed Oct 28 9:30am Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity? Induced proximity beyond degradation Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 2:15pm GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening Screening, assays & proteomics |
Arvinas New Haven, CT | |
Biotech developing PROTAC protein degraders for cancer and neurological diseases. | Talk Tue Oct 27 8:30am Degradation Delivered – What the First TPD Approval Means for the Future of the Field Translational & clinical developmentInvestment, partnering & strategy |
Foghorn Therapeutics Cambridge, MA | |
Clinical-stage biotech targeting the chromatin regulatory system with small molecules and protein degraders for cancer. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 10:30am Proximity by Design: Harnessing Induced Proximity for Challenging Targets Degrader discovery & design |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company developing and marketing medicines in oncology, immunology, cardiovascular disease and neuroscience. | Talk Tue Oct 27 5:00pm Modelling Targeted Protein Degradation from Cells to the Clinic AI & computational design Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
C4 Therapeutics Watertown, MA | |
Clinical-stage biotech developing small-molecule targeted protein degraders for cancer. | Chair Tue Oct 27 8:20am Chair’s Opening Remarks Investment, partnering & strategy Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 11:45am |
Develops targeted protein degraders that disrupt cancer cell fitness, including the PIP4K2C degrader LRK-4189. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy |
Develops targeted protein stabilization therapeutics that recruit deubiquitinases to rescue proteins rather than degrade them. | Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Wed Oct 28 2:00pm The Journey to DUBTAC Clinical Candidates Induced proximity beyond degradation |
Flagship Pioneering Cambridge, MA | |
Company-creation firm that founds, builds and funds biotech companies. | Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Johnson & Johnson New Brunswick, NJ | |
Healthcare company whose Innovative Medicine segment develops medicines in oncology, immunology and neuroscience. | Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Merck & Co. Rahway, NJ | |
Global pharmaceutical company, known as MSD outside the US and Canada, developing medicines, vaccines and biologics. | Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Qiming Venture Partners Shanghai, China | |
Venture capital firm investing in healthcare and technology companies in China and the US. | Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Instantly find 20 buyers in investment, partnering & strategy
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction